Breaking News, Collaborations & Alliances

Telix Chooses Goodwin Bio as Mfg. Scale-up Partner

CDMO to optimize the process for cGMP manufacturing of Telix's renal cancer imaging ADC TLX-250

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Telix Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has selected Goodwin Biotechnology to optimize the process for cGMP manufacturing of its renal cancer imaging antibody drug conjugate TLX-250. The product will be used in Telix’s Phase III clinical study for the diagnostic imaging and staging of patients with clear ce...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters